The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
A lot is riding on whether its platform is valuable, or vaporware.
Morgan Stanley is betting on these stocks to benefit from the AI megatrend.
Recursion is playing the long game with its AI-focused approach to drug discovery and development.
They might not be profitable yet, but they're swinging for the fences.
This stock's upside is huge, but so is its downside.
The company just made a provocative move in one of its collaborations.
The company had attracted much interest due to its heavy use of artificial intelligence, but its latest fundamentals disappointed many.
These companies are focused on next-gen technologies that could help transform the healthcare industry.